Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
Summary
- As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025.
- It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises.
- So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.
- In addition, sales of Vyalev, approved by the FDA only on October 17, 2024, for the treatment of advanced Parkinson's disease, have already amounted to $63 million.
- In this article, you will learn about extra reasons why I continue to cover AbbVie with a 'Strong Buy' rating.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.